Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/08/2022 | Series B | $118MM | $xx.xx | $26.74B | Adams Street Partners, Andera Partners, Boulder Ventures, Catalys Pacific, Hbm Healthcare Investments, Healthcor Management, Ra Capital Management, Rock Springs Capital, Rtw Investments, Samsara Biocapital, Sectoral Asset Management, Sr One Capital Management, Ysis Capital | |
Price per Share
$xx.xx
Shares Outstanding
136,510,868
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Adams Street Partners, Andera Partners, Boulder Ventures, Catalys Pacific, Hbm Healthcare Investments, Healthcor Management, Ra Capital Management, Rock Springs Capital, Rtw Investments, Samsara Biocapital, Sectoral Asset Management, Sr One Capital Management, Ysis Capital
|
||||||
04/06/2021 | Series A | $41.18MM | $xx.xx | $8.24B | Adams Street Partners, Catalys Pacific, Hbm Healhcare Investments, Samsara Biocapital | |
Price per Share
$xx.xx
Shares Outstanding
86,332,216
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Adams Street Partners, Catalys Pacific, Hbm Healhcare Investments, Samsara Biocapital
|